Global Biosimilars Market Forecast to 2015
The biosimilars industry has been growing stupendously across the globe for past few years. Increasing healthcare costs and rising aging population are driving the industry, which stands at a vivid position and is expected to evolve greatly from its current state. As per the estimations of our latest report, the global biosimilars market will grow at a CAGR of around 52% during 2010-2015. With the governments and private players worldwide stepping in the industry, the market shows bright prospects and immense opportunities to cash in on.
According to “Global Biosimilars Market Forecast to 2015”, the first-generation biosimilars currently dominate the market, and their second-generation is expected to grow stupendously in the future. Our report provides a thorough study of the biosimilars market, and its segmentation at the product and country level. We have carried out a detailed market-segmentation analysis in the study, which presents forecasts on the first-generation biosimilars. Key developments in each segment have also been highlighted in it to tell ‘what is going on’ in the market.
For key regulated and unregulated markets including the US, Europe, India, China and Korea, the geographic-segmentation has been included. Our research has studied the overall industry performance and key biosimilar products in the market, and found that patent expirations offer a huge potential to new market entrants. The recent industry activities have been tracked, and the regulatory scenario has been analyzed to provide an impartial picture of the industry to clients.
We have covered the key market players in different geographies, and provided in the report a look at their activities, recent developments and key biosimilar products. We observed that players such as Sandoz/Novartis AG, Hospira and Teva are the global market leaders. Overall, the report aims at providing complete information about the biosimilar industry to clients who are planning to enter the biosimilars market.
According to “Global Biosimilars Market Forecast to 2015”, the first-generation biosimilars currently dominate the market, and their second-generation is expected to grow stupendously in the future. Our report provides a thorough study of the biosimilars market, and its segmentation at the product and country level. We have carried out a detailed market-segmentation analysis in the study, which presents forecasts on the first-generation biosimilars. Key developments in each segment have also been highlighted in it to tell ‘what is going on’ in the market.
For key regulated and unregulated markets including the US, Europe, India, China and Korea, the geographic-segmentation has been included. Our research has studied the overall industry performance and key biosimilar products in the market, and found that patent expirations offer a huge potential to new market entrants. The recent industry activities have been tracked, and the regulatory scenario has been analyzed to provide an impartial picture of the industry to clients.
We have covered the key market players in different geographies, and provided in the report a look at their activities, recent developments and key biosimilar products. We observed that players such as Sandoz/Novartis AG, Hospira and Teva are the global market leaders. Overall, the report aims at providing complete information about the biosimilar industry to clients who are planning to enter the biosimilars market.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. BIOLOGICS MARKET OUTLOOK TO 2015
3.1 Market Size
3.2 Market Segmentation
3.3 Country Level Analysis
4. MARKET TRENDS & DRIVERS
4.1 Cancer Indications Driving the Biosimilar Race
4.2 Rising Business Alliances Aiding in Biosimilar Development
4.3 Governments Realizing the Potential in Biosimilars, Encouraging Industry Growth
4.4 Biosimilar Players in US to Prefer BLA over Abbreviated Pathway
5. BIOSIMILARS MARKET OUTLOOK TO 2015
5.1 Market Size
5.2 Market Segmentation
5.2.1 Erythropoietin
5.2.1.1 Scientific Insight
5.2.1.2 Market Analysis
5.2.1.3 Recent Activities
5.2.2 Human Growth Hormone
5.2.2.1 Scientific Insight
5.2.2.2 Market Analysis
5.2.2.3 Recent Activities
5.2.3 G-CSF
5.2.3.1 Scientific Insight
5.2.3.2 Market Analysis
5.2.3.3 Recent Activities
5.2.4 Monoclonal Antibody
5.2.4.1 Scientific Insight
5.2.4.2 Market Analysis
5.2.4.3 Recent Activities
5.2.5 Human Insulin
5.2.5.1 Scientific Insight
5.2.5.2 Market Analysis
5.2.5.3 Recent Activities
5.2.6 Interferons
5.2.6.1 Scientific Insight
5.2.6.2 Market Analysis
6. MAJOR GEOGRAPHICAL MARKET
6.1 US
6.1.1 Market Analysis
6.1.2 Regulatory Analysis
6.1.3 Recent Activities
6.2 Europe
6.2.1 Market Analysis
6.2.2 Regulatory Analysis
6.2.3 Recent Activities
6.3 India
6.3.1 Market Analysis
6.3.2 Regulatory Analysis
6.3.3 Recent Activities
6.4 China
6.4.1 Market Analysis
6.4.2 Regulatory Analysis
6.4.3 Recent Activities
6.5 Korea
6.5.1 Market Analysis
6.5.2 Regulatory Analysis
6.5.3 Recent Activities
7. COMPETITIVE LANDSCAPE (KEY PRODUCTS AND RECENT ACTIVITIES)
7.1 US
7.1.1 Hospira
7.2 Europe
7.2.1 Stada Arzneimittel
7.2.2 Hexal AG
7.2.3 Ratiopharm GmbH
7.2.4 Sandoz GmbH
7.2.5 Bioton
7.3 India
7.3.1 Dr.Reddy's Labs (DRL)
7.3.2 Intas Pharmaceuticals Ltd.
7.3.3 Biocon Limited
7.3.4 Wockhardt Limited
7.3.5 Shantha Biotechnics Limited
7.3.6 Reliance Life Sciences
7.4 China
7.4.1 3 SBio Inc.
7.4.2 Beijing Tri-Prime
7.4.3 Beijing SL Pharmaceutical Co., Ltd.
7.4.4 Shandong Kexing Biological Products Co., Ltd
7.4.5 Hangzhou Jiuyuan Gene Engineering
7.5 Korea
7.5.1 LG Life Sciences
7.5.2 Celltrion Pharm Inc.
7.5.3 Dong-A Pharmaceutical Co., Ltd
7.6 Others
7.6.1 Teva
7.6.2 Cangene Corporation
7.6.3 Microbix Biosystems, Inc.
2. RESEARCH METHODOLOGY
3. BIOLOGICS MARKET OUTLOOK TO 2015
3.1 Market Size
3.2 Market Segmentation
3.3 Country Level Analysis
4. MARKET TRENDS & DRIVERS
4.1 Cancer Indications Driving the Biosimilar Race
4.2 Rising Business Alliances Aiding in Biosimilar Development
4.3 Governments Realizing the Potential in Biosimilars, Encouraging Industry Growth
4.4 Biosimilar Players in US to Prefer BLA over Abbreviated Pathway
5. BIOSIMILARS MARKET OUTLOOK TO 2015
5.1 Market Size
5.2 Market Segmentation
5.2.1 Erythropoietin
5.2.1.1 Scientific Insight
5.2.1.2 Market Analysis
5.2.1.3 Recent Activities
5.2.2 Human Growth Hormone
5.2.2.1 Scientific Insight
5.2.2.2 Market Analysis
5.2.2.3 Recent Activities
5.2.3 G-CSF
5.2.3.1 Scientific Insight
5.2.3.2 Market Analysis
5.2.3.3 Recent Activities
5.2.4 Monoclonal Antibody
5.2.4.1 Scientific Insight
5.2.4.2 Market Analysis
5.2.4.3 Recent Activities
5.2.5 Human Insulin
5.2.5.1 Scientific Insight
5.2.5.2 Market Analysis
5.2.5.3 Recent Activities
5.2.6 Interferons
5.2.6.1 Scientific Insight
5.2.6.2 Market Analysis
6. MAJOR GEOGRAPHICAL MARKET
6.1 US
6.1.1 Market Analysis
6.1.2 Regulatory Analysis
6.1.3 Recent Activities
6.2 Europe
6.2.1 Market Analysis
6.2.2 Regulatory Analysis
6.2.3 Recent Activities
6.3 India
6.3.1 Market Analysis
6.3.2 Regulatory Analysis
6.3.3 Recent Activities
6.4 China
6.4.1 Market Analysis
6.4.2 Regulatory Analysis
6.4.3 Recent Activities
6.5 Korea
6.5.1 Market Analysis
6.5.2 Regulatory Analysis
6.5.3 Recent Activities
7. COMPETITIVE LANDSCAPE (KEY PRODUCTS AND RECENT ACTIVITIES)
7.1 US
7.1.1 Hospira
7.2 Europe
7.2.1 Stada Arzneimittel
7.2.2 Hexal AG
7.2.3 Ratiopharm GmbH
7.2.4 Sandoz GmbH
7.2.5 Bioton
7.3 India
7.3.1 Dr.Reddy's Labs (DRL)
7.3.2 Intas Pharmaceuticals Ltd.
7.3.3 Biocon Limited
7.3.4 Wockhardt Limited
7.3.5 Shantha Biotechnics Limited
7.3.6 Reliance Life Sciences
7.4 China
7.4.1 3 SBio Inc.
7.4.2 Beijing Tri-Prime
7.4.3 Beijing SL Pharmaceutical Co., Ltd.
7.4.4 Shandong Kexing Biological Products Co., Ltd
7.4.5 Hangzhou Jiuyuan Gene Engineering
7.5 Korea
7.5.1 LG Life Sciences
7.5.2 Celltrion Pharm Inc.
7.5.3 Dong-A Pharmaceutical Co., Ltd
7.6 Others
7.6.1 Teva
7.6.2 Cangene Corporation
7.6.3 Microbix Biosystems, Inc.
LIST OF FIGURES
Figure 3-1: Global - Biologics Market (Billion US$), 2010-2015
Figure 3-2: Global - Biologics Market by Segment (%), 2010
Figure 3-3: Global - Share of Country/Region in Biologics Market
Figure 5-1: Global - Biosimilars Market (Million US$), 2010 & 2015
Figure 5-2: Global - Biosimilars Market by Key Segment (%), 2010
Figure 5-3: Global - Erythropoietin Biosimilars Market (Million US$), 2010-2015
Figure 5-4: Global - HGH Biosimilars Market (Million US$), 2010-2015
Figure 5-5: Global - G-CSF Biosimilars Market (Million US$), 2010-2015
Figure 3-1: Global - Biologics Market (Billion US$), 2010-2015
Figure 3-2: Global - Biologics Market by Segment (%), 2010
Figure 3-3: Global - Share of Country/Region in Biologics Market
Figure 5-1: Global - Biosimilars Market (Million US$), 2010 & 2015
Figure 5-2: Global - Biosimilars Market by Key Segment (%), 2010
Figure 5-3: Global - Erythropoietin Biosimilars Market (Million US$), 2010-2015
Figure 5-4: Global - HGH Biosimilars Market (Million US$), 2010-2015
Figure 5-5: Global - G-CSF Biosimilars Market (Million US$), 2010-2015
LIST OF TABLES
Table 4-1: Global - Pipeline Biosimilar Products of Key Players against Cancer
Table 5-1: Global - Marketed EPO Biosimilar Products of Key Players
Table 5-2: Global - Pipeline EPO Biosimilar Products of Key Players
Table 5-3: Global - Marketed HGH Biosimilar Products of Key Players
Table 5-4: Global - Marketed G-CSF Biosimilar Products of Key Players
Table 5-5: Global - Pipeline G-CSF Biosimilar Products of Key Players
Table 5-6: Global - Marketed mAb Biosimilar Products of Key Players
Table 5-7: Global - Pipeline mAB Biosimilar Products of Key Players
Table 5-8: Global - Marketed Insulin Biosimilar Products of Key Players
Table 5-9: Global - Pipeline Insulin Biosimilar Products of Key Players
Table 5-10: Global - Marketed Interferon Biosimilar Products of Key Players
Table 5-11: Global - Pipeline Interferon Biosimilar Products of Key Players
Table 6-1: US - Annual Prescription Costs/Person for Key Biologics
Table 6-2: US - Patent Expiries of Key Biologics
Table 6-3: Europe - Approved Biosimilar Products (2010)
Table 6-4: Europe - Patent Expiries of Key Biologics
Table 6-5: India - Key Approved Biosimilar Products
Table 6-6: China - Key Approved Biosimilar Products
Table 6-7: Korea - Key Approved Biosimilar Products
Table 6-8: Korea - Key Biosimilar Products in Pipeline
Table 6-9: Korea - Patent Expiries of Key Biologics
Table 4-1: Global - Pipeline Biosimilar Products of Key Players against Cancer
Table 5-1: Global - Marketed EPO Biosimilar Products of Key Players
Table 5-2: Global - Pipeline EPO Biosimilar Products of Key Players
Table 5-3: Global - Marketed HGH Biosimilar Products of Key Players
Table 5-4: Global - Marketed G-CSF Biosimilar Products of Key Players
Table 5-5: Global - Pipeline G-CSF Biosimilar Products of Key Players
Table 5-6: Global - Marketed mAb Biosimilar Products of Key Players
Table 5-7: Global - Pipeline mAB Biosimilar Products of Key Players
Table 5-8: Global - Marketed Insulin Biosimilar Products of Key Players
Table 5-9: Global - Pipeline Insulin Biosimilar Products of Key Players
Table 5-10: Global - Marketed Interferon Biosimilar Products of Key Players
Table 5-11: Global - Pipeline Interferon Biosimilar Products of Key Players
Table 6-1: US - Annual Prescription Costs/Person for Key Biologics
Table 6-2: US - Patent Expiries of Key Biologics
Table 6-3: Europe - Approved Biosimilar Products (2010)
Table 6-4: Europe - Patent Expiries of Key Biologics
Table 6-5: India - Key Approved Biosimilar Products
Table 6-6: China - Key Approved Biosimilar Products
Table 6-7: Korea - Key Approved Biosimilar Products
Table 6-8: Korea - Key Biosimilar Products in Pipeline
Table 6-9: Korea - Patent Expiries of Key Biologics
